Tag: annual report

INDIANAPOLIS, June 17, 2025 (GLOBE NEWSWIRE) -- Kite Realty Group Trust (NYSE: KRG) (the “Company”) announced today that, on June 17, 2025, its operating partnership, Kite Realty Group, L.P. (the “Operating Partnership”), priced an offering of $300 million aggregate principal amount of 5.200% Senior Notes due 2032 (the “Notes”) in an underwritten public offering. The Notes will be issued at 99.513% of par value with a yield to maturity of 5.281%. Interest on the Notes is payable semi-annually on February 15 and August 15 of each year, beginning on February 15, 2026. The offering is expected to close on June 27, 2025, subject to the satisfaction of customary closing conditions.

REDWOOD CITY, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, announced today that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof) and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof). In addition, Biomea intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock and pre-funded warrants offered in the public offering. All of the shares, pre-funded warrants and accompanying common stock warrants to be sold in the proposed offering are to be sold by Biomea.

Fiscal 2025 Fourth Quarter Highlights:

On Track to Exit Financial Reorganization Process Next Week, Company to Focus on Scaled Delivery of Its Comprehensive, Best-in-Class Weight Management Platform, Integrating Community, Behavioral, and Medical Solutions

17 June 2025

Transaction highlights strategic execution and unlocks capital for highly accretive Spetner Acquisition

Company Announcement

Luxembourg – 17 June 2025 - Subsea 7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) today announced the award of a substantial¹ contract offshore Norway. 

MONTREAL, June 17, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today that it has completed the acquisition of the Paladin business, under the terms of the definitive Asset Purchase Agreement (“APA”) entered with Paladin Pharma Inc., an Endo, Inc. operating company, as announced in March 2025.

SOUTH SAN FRANSCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of  engineered T cell therapeutics that deploy phagocytic mechanisms, announces that the U.S. Food and Drug Administration (FDA) has granted CERo’s Orphan Drug Designation (ODD) for the company's lead drug candidate CER-1236, for the treatment of acute myeloid leukemia (AML). CER-1236 is an innovative therapy that engineers a cancer patient's own T cell therapeutics that deploy phagocytic (i.e., target-cell eating) mechanisms alongside the array of built-in target cell destroying mechanisms used by T cells.

- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications -